Medication vs Medication
Mounjaro vs Saxenda
A practical UK comparison focused on what is genuinely different — not which brand has the loudest marketing.
Mounjaro
Up to ~20%+ mean loss in obesity trials; direct head-to-head 20.2% at 72 weeks vs 13.7% semaglutide 1.7/2.4 mg in SURMOUNT-5
Liraglutide (Saxenda / licensed equivalents)
Large adult trial: mean -8.0% at 56 weeks vs -2.6% placebo
Side-by-side
| Mounjaro | Liraglutide (Saxenda / licensed equivalents) | |
|---|---|---|
| Active ingredient | tirzepatide | liraglutide |
| Form | Weekly injection | Daily injection |
| Frequency | Once weekly | Once daily |
| Licence | UK weight management licence | UK weight management licence |
| NHS context | NICE-recommended; NHS access is phased / pathway-dependent | NICE option in specialist services for defined groups; pathway availability varies |
| Evidence | Very strong | Mature |
| Weight-loss evidence | Up to ~20%+ mean loss in obesity trials; direct head-to-head 20.2% at 72 weeks vs 13.7% semaglutide 1.7/2.4 mg in SURMOUNT-5 | Large adult trial: mean -8.0% at 56 weeks vs -2.6% placebo |
| Maintenance | Long-term treatment may be needed; stopping can be followed by regain | Ongoing treatment and maintenance strategy matter |
| GI considerations | Common GI effects, especially during escalation | GI effects common; daily dosing can add burden |
Reasons to discuss Mounjaro
- Highest head-to-head mean weight loss among the established injectable options in SURMOUNT-5
- Weekly dosing
- Strong appetite / food-noise effect for many users
- Weight-management and maintenance licence
Trade-offs
- Injection
- GI side effects can be limiting
- Access and NHS rollout are not the same as NICE eligibility
- Ongoing treatment cost/maintenance matters if private
Reasons to discuss Liraglutide (Saxenda / licensed equivalents)
- Longer track record in obesity treatment
- GLP-1 mechanism
- Can be appropriate where other options are unsuitable
- Licensed specifically for weight management
Trade-offs
- Daily injection
- Lower average weight loss than newer weekly incretin treatments
- NHS use is restricted
- Daily adherence burden
Which is stronger for weight loss?
Mounjaro is rated 10/10 and Liraglutide (Saxenda / licensed equivalents) 5/10 in our comparison framework. That rating summarises the obesity evidence available for the licensed formulation; it is not a prediction of your result.
Which is easier to live with?
Mounjaro: Once weekly. Liraglutide (Saxenda / licensed equivalents): Once daily. For some people a weekly injection is easier than a daily tablet; for others avoiding a needle is decisive.
NHS vs private reality
NICE-recommended; NHS access is phased / pathway-dependent. NICE option in specialist services for defined groups; pathway availability varies. NICE criteria and NHS availability are related but not identical, so check the current pathway rather than assuming a clinically eligible medicine is immediately available through a GP.
Maintenance matters
Long-term treatment may be needed; stopping can be followed by regain. Ongoing treatment and maintenance strategy matter. A treatment comparison that ends at the point of weight loss is incomplete.
Questions to ask a prescriber
- Which option is actually licensed and clinically appropriate for my health history?
- How do the expected benefits compare for someone with my diabetes/cardiovascular history?
- What side effects should make me contact you?
- What will monitoring involve?
- What is the plan if I cannot tolerate the maintenance dose?
- What happens if I stop?
Sources
Continue exploring